Related by context. All words. (Click for frequent words.) 72 trastuzumab DM1 T DM1 72 ToGA 70 PSMA ADC 70 PI3K/Akt pathway inhibitor 70 elotuzumab 70 Prostate AdenoCarcinoma Treatment 70 alvespimycin 70 multicenter Phase II 70 mertansine 70 YONDELIS 70 preclinical efficacy 69 MAGE A3 ASCI 69 Phase Ib II 69 BRIM3 69 pharmacokinetic PK study 69 JAK inhibitor 69 Phase Ib clinical 69 Phase 1a clinical 68 EDEMA3 68 neratinib 68 Oral NKTR 68 huC# DM4 68 AVOREN 68 phase IIb clinical 68 Phase Ib study 68 liposomal formulation 68 Rigel R# 68 HuMax EGFr 68 Azedra 68 Phase 1b clinical trials 68 EXPLORE Xa 68 Alocrest 67 Virulizin ® 67 HCV RESPOND 2 67 CHAMPION PCI 67 oral ridaforolimus 67 phase IIa clinical 67 ENMD # 67 Vectibix panitumumab 67 LUX Lung 67 evaluating mipomersen 67 randomized Phase III 67 NO# [002] 67 placebo controlled clinical 67 HGS# 67 Phase IIb III 67 cathepsin K inhibitor 67 dose escalation Phase 67 Phase 1b clinical 67 phase IIb trial 67 OncoVEX GM CSF 67 metaglidasen 67 paclitaxel Taxol ® 67 ularitide 67 DEB# 67 HCV SPRINT 67 evaluating satraplatin 67 evaluating REVLIMID 67 ongoing Phase 1b 67 UPLYSO 67 OvaRex ® MAb 67 ZACTIMA 66 GRNVAC1 66 Fludara ® 66 pertuzumab 66 MEND CABG 66 BRIM2 66 galiximab 66 Aplidin 66 evaluating tivozanib 66 INCB# [001] 66 RGB # 66 deforolimus 66 CANCIDAS 66 trastuzumab Herceptin ® 66 Phase #/#a 66 R roscovitine 66 Quinamed 66 cediranib 66 PDE4 inhibitor 66 HGS ETR2 66 gemcitabine carboplatin 66 Archexin 66 axitinib 66 sunitinib malate 66 multicenter randomized placebo controlled 66 Telatinib 66 relapsed MM 66 nucleotide analog 66 Proellex TM 66 forodesine 66 ANCHOR trial 66 phase IIa 66 randomized controlled multicenter 66 ocular formulation 66 AKT inhibitor 66 HER2 positive metastatic breast 66 Phase IIIb clinical 66 LymphoStat B belimumab 66 Zemplar Capsules 66 phase IIb 66 GAMMAGARD 66 pharmacokinetic PK 66 HCV protease inhibitor 66 Temsirolimus 66 confirmatory clinical 66 Trastuzumab DM1 66 TMC# C# 65 trastuzumab Herceptin R 65 TBC# 65 DermaVir Patch 65 vidofludimus 65 REMINYL ® 65 Solorel TM 65 fenofibric acid 65 Panzem R NCD 65 dose escalation clinical 65 Phase IIB 65 enzastaurin 65 MGd 65 blinded randomized placebo controlled 65 Aplidin R 65 Afatinib 65 phase IIIb 65 FOLOTYN ® 65 ZYBRESTAT fosbretabulin 65 Vaxfectin R 65 CCX# 65 CIMZIA ™ 65 Phase #b/#a clinical 65 Saforis 65 Hedgehog Pathway Inhibitor 65 BR.# 65 Exelixis compounds 65 Glufosfamide 65 bazedoxifene conjugated estrogens 65 pomalidomide 65 NSABP B 65 multicentre randomized 65 randomized Phase 2b 65 non nucleoside HCV 65 thorough QT 65 EURIDIS 65 NEUVENGE 65 GSK# [001] 65 Trandolapril 65 KRN# 65 AVADO 65 pain palliation 65 RE LY ® 65 dosing cohorts 65 Aflibercept 65 investigational humanized monoclonal antibody 65 Tarceva TM 65 PEG SN# 65 vicriviroc 65 OvaRex MAb 65 double blinded randomized 65 PrevOnco ™ 65 genotypic resistance 65 Elvitegravir 65 Pharmacokinetic parameters 65 depsipeptide 65 urocortin 2 65 pegylated liposomal doxorubicin 65 GW# [003] 65 tolevamer 65 Hsp# Inhibitor 65 sorafenib Nexavar 65 XL# XL# XL# XL# 65 Deforolimus 65 pan HDAC inhibitor 65 goserelin 65 Pharmacokinetic PK 65 huN# DM1 65 BiTE R 65 riociguat 65 XmAb# 65 Ozarelix 65 fosbretabulin 65 Xanafide 65 Phase 2a trial 65 romidepsin 65 GetGoal Phase III 65 novel VDA molecule 65 placebo controlled Phase III 65 fidaxomicin Phase 3 64 MERLIN TIMI 64 rALLy clinical trial 64 PRIMO CABG2 64 tanespimycin 64 docetaxel Taxotere ® 64 CYT# potent vascular disrupting 64 TRX1 64 Traficet EN 64 Ceplene/IL-2 64 Cervista HPV HR 64 phase 2a 64 IMPACT IMmunotherapy 64 eprotirome 64 lorvotuzumab mertansine 64 virus HCV protease inhibitor 64 AEGR 64 preclinically 64 teriflunomide 64 non nucleoside inhibitor 64 Pertuzumab 64 IMA# 64 gemcitabine Gemzar 64 ThermoDox ® clinical 64 BCIRG 64 investigational protease inhibitor 64 double blinded placebo 64 antiviral efficacy 64 controlled multicenter Phase 64 Amrubicin 64 iniparib 64 adecatumumab 64 PrevOnco 64 SUCCEED trial 64 solithromycin 64 BAY #-# 64 LymphoStat B TM 64 PARTNER Trial 64 elacytarabine 64 multicenter Phase III 64 PROSTVAC TM 64 CRLX# 64 oral prodrug 64 ORAL Sync 64 sapacitabine CYC# 64 candidate CRLX# 64 tesmilifene 64 thymalfasin 64 STRIDE PD 64 Bayer HealthCare Onyx Pharmaceuticals 64 sorafenib tablets 64 SPRYCEL ® 64 viral kinetic 64 docetaxel Taxotere R 64 Cloretazine 64 trastuzumab DM1 64 PRIMO CABG 64 GSK# [002] 64 prospective randomized multicenter 64 dextromethorphan quinidine 64 Apoptone 64 Genz # 64 tramiprosate Alzhemed TM 64 OncoVEX 64 CLORETAZINE TM VNP#M 64 CTAP# Capsules 64 plasma kallikrein inhibitor 64 proteasome inhibitor 64 placebo controlled multicenter 64 Androxal TM 64 randomized controlled Phase 64 Tesmilifene 64 panitumumab Vectibix 64 PHX# 64 Tanespimycin 64 EDEMA4 64 Silodosin 64 Safinamide 64 PANVAC VF 64 mRCC 64 Reverset 64 pharmacodynamic PD 64 TPI ASM8 64 Randomized Phase II 64 P#X# antagonist 64 OncoVex 64 GATTEX ® 64 Dacogen injection 64 OMP #M# 64 ritonavir boosted 64 Phase IIb clinical trials 64 SUTENT ® 64 Dapagliflozin 64 subcutaneous PRO 64 vinca alkaloid 64 sorafenib Nexavar ® 64 multicenter multinational 64 tolerability pharmacokinetics 64 Tyrima 64 ganetespib 64 Hyphanox 63 Xelox 63 EXPAREL ™ 63 TransVax TM 63 Plicera 63 brivanib 63 zotarolimus 63 multicenter placebo controlled 63 novel histone deacetylase 63 Kahalalide F 63 crizotinib PF # 63 REGN# 63 LHRH antagonists 63 NXL# 63 Multiple Ascending Dose 63 FOLFOX6 chemotherapy regimen 63 metastatic HRPC 63 refractory gout 63 nucleotide analogue 63 HGS ETR1 mapatumumab 63 indibulin 63 obatoclax 63 phase Ib 63 EGFR HER2 63 ELACYT 63 cannabinor 63 velafermin 63 acyclovir Lauriad R 63 Omnitarg 63 demonstrated antitumor activity 63 prospective multicentre 63 placebo controlled Phase 63 PDX pralatrexate 63 Phase 1b trial 63 RE LY 63 orally administered inhibitor 63 CLL8 63 Dasatinib 63 volociximab 63 Onconase 63 Vicriviroc 63 bicifadine 63 angiogenesis inhibitor 63 R#/MEM # 63 Lenocta 63 Pemetrexed 63 NP2 Enkephalin 63 refractory chronic lymphocytic 63 Clinicaltrials.gov 63 Bezielle 63 K ras mutations 63 HuLuc# 63 arzoxifene 63 GALNS 63 mapatumumab 63 RezularTM 63 sitaxsentan 63 fluvastatin 63 dose escalation trial 63 vemurafenib 63 Pazopanib 63 Sym# 63 farletuzumab 63 pharmacodynamic profiles 63 pharmacokinetics PK 63 sNDA submission 63 MIVI TRUST 63 interferon gamma 1b 63 MVA MUC1 IL2 63 aleglitazar 63 radiation dosimetry 63 radiation sensitizer 63 ABSORB trial 63 DU #b 63 oral deforolimus 63 aflibercept 63 bepotastine besilate nasal spray 63 evaluating T DM1 63 MKC# MT 63 PROSTVAC ® 63 bevacizumab Avastin ® 63 anti CD3 antibody 63 QuadraSphere 63 2 inhibitor CYT# 63 XL# SAR# 63 nalbuphine ER 63 desvenlafaxine succinate 63 active comparator 63 HGS ETR1 63 miRview meso 63 Phase 2a clinical 63 SAR# [004] 63 registrational Phase 63 ASTEROID 63 docetaxel chemotherapy 63 formal pharmacokinetic PK 63 pramlintide metreleptin combination 63 HuMax CD4 63 alkylating agent 63 Ophena 63 posaconazole 63 CR# vcMMAE 63 fluoropyrimidine 63 SPIRIT FIRST 63 MYDICAR ® 63 PRT# 63 Zenvia ™ 63 Vitaxin 63 TACI Ig 63 regorafenib 63 assessing T DM1 63 pivotal bioequivalence 63 APEX PD 63 Aurexis 63 CBLC# 63 cytokine refractory 63 Darinaparsin 63 initiate multicenter 63 ADVANCE PD 63 canakinumab 63 clinical pharmacology studies 63 registrational trial 63 pharmacokinetic equivalence 63 ThermoDox R 63 Phase IIa trials 63 resminostat 63 LB# [003] 63 oral taxane 63 IMC A# 63 HCV protease inhibitors 63 brivaracetam 63 entinostat 63 CTA# Injection 63 Spiegelmer ® 63 Carfilzomib 63 cilengitide 63 MKC# MKC# PP 63 receptor inhibitor 63 Zolinza 63 Degarelix 63 Xeloda ® 63 DASISION 63 S/GSK# 63 Phase Ib 63 aurora kinase 63 efficacy endpoint 63 vitro cytotoxicity 63 GOUT 63 receptor tyrosine kinase inhibitor 63 cisplatin gemcitabine 63 Amplimexon 63 pharmacodynamic effects 63 multicenter phase 63 Akt inhibitor 63 metastatic colorectal carcinoma 63 LUMINATE 63 tubulin inhibitor 62 trodusquemine 62 Thalomid ® 62 ARIKACE ™ 62 please visit www.advaxis.com 62 Elagolix 62 Proxinium TM 62 ceftazidime 62 HQK 62 hA# 62 lexidronam injection 62 Phase lll 62 treatment naive genotype 62 Ophena TM 62 IMiDs ® 62 RAS MAPK pathway 62 AVASTIN 62 PS# [001] 62 NB S# strontium malonate 62 raltegravir 62 JAK inhibitors 62 randomized multicenter Phase III 62 Nexavar sorafenib 62 GLP toxicology studies 62 AEG# 62 pharmacokinetic pharmacodynamic 62 Phase #b/#a 62 ON #.Na 62 racemic baclofen 62 CD# CEA 62 telomerase therapeutic 62 plasmid DNA vaccine 62 PD LID 62 confirmatory pivotal 62 including eniluracil ADH 62 Matrix Phase 2b 62 Randomized Phase 62 polymerase inhibitor 62 VIR# 62 SPL# Gel vaginal microbicide 62 phase IIb study 62 myelofibrosis polycythemia vera 62 TransVax tm 62 opioid induced bowel dysfunction 62 CEQ# 62 pharmacokinetic PK profile 62 florbetaben 62 CAMMS# 62 Tolvaptan 62 oral rivaroxaban 62 recurrent NSCLC 62 mg BID dose 62 Epirubicin 62 sulodexide 62 bevirimat Study 62 Elitek 62 antitumor activity 62 Luteinizing Hormone Releasing Hormone 62 miconazole Lauriad ® 62 lintuzumab SGN 62 eliglustat tartrate 62 registrational 62 MEK inhibitor RDEA# 62 seliciclib CYC# 62 brostallicin 62 HORIZONS AMI trial 62 CIP TRAMADOL ER 62 CORT # 62 SCH # 62 Vaxfectin TM 62 lumiliximab 62 dextofisopam 62 evaluating Actimmune 62 Allovectin 7 ® 62 CCR5 antagonist 62 unique alkylating agent 62 Phase IIIb 62 novel oral anticoagulant 62 prospective multicenter randomized 62 rilpivirine 62 Pharmacodynamic 62 Phase 2b study 62 phase IIb III 62 adenosine injection 62 drug pipeline TAFA# 62 SYMMETRY trial 62 PEG INTRON R 62 REVIVE TA 62 standard chemotherapy regimen 62 EGS# 62 Teriflunomide 62 dacetuzumab 62 EndoTAG TM -1 62 bosutinib 62 ZOLINZA 62 HCV NS5B polymerase 62 Phase #/#a trial 62 HIV integrase inhibitor 62 inhibitor RG# 62 oral picoplatin 62 Faslodex 62 gastrin analogue TT 62 bardoxolone 62 BRAF inhibitor 62 ongoing Phase IIIb 62 pradefovir 62 ACCORD Lipid 62 CINQUIL 62 Prodarsan ® 62 siRNAs targeting 62 CanAg 62 Imprime PGG 62 MORAb 62 telaprevir dosed 62 FOLFOX6 62 ACZ# 62 LHRH receptor positive 62 Phase IIb clinical 62 PRECiSE 62 Chrysalin 62 INSPIRE Trial Phase III 62 Mipomersen 62 TKB# 62 PORxin TM platforms 62 lomitapide 62 CALGB 62 Symadex 62 multiple myeloma MM 62 lenalidomide dexamethasone 62 ACTEMRA TM 62 selective androgen receptor modulator 62 IL# PE#QQR 62 BZL# 62 erlotinib Tarceva ® 62 IMiDs R 62 perifosine KRX 62 cisplatin vinorelbine 62 TASKi2 62 phase Ib clinical 62 orally dosed 62 multi kinase inhibitor 62 EDEMA3 trial 62 IMC #B 62 multicenter randomized controlled 62 Genasense oblimersen sodium Injection 62 randomized Phase IIb 62 EOquin 62 MEND CABG II 62 vascular disrupting agent 62 Onrigin 62 synthetic retinoid 62 clevidipine 62 interleukin IL -# 62 diarrhea predominant irritable 62 randomized multicentre 62 GAP #B# 62 EOquin TM 62 IFN α 62 RELOVAIR ™ 62 reslizumab 62 ASPIRE HIGHER 62 Tesetaxel 62 Hepatocellular Carcinoma HCC 62 APTIVUS 62 gallium containing 62 prospectively defined 62 recurrent metastatic ovarian cancer 62 Phase 2b clinical 62 clinico pathological 62 Phase Ia 62 HPTN 62 selective orally bioavailable 62 p# biomarker 62 Velcade bortezomib 62 multicenter randomized Phase III 62 TransVax ™ 62 Maximum Tolerated Dose MTD 62 XL# anticancer compounds 62 Tarvacin TM 62 Phase IIA 62 GLYX 62 CD# antibody [001] 62 trabectedin 62 TG# [003] 62 BrachySil TM 62 Copegus R 62 randomized discontinuation trial 62 retapamulin 62 acyclovir Lauriad ® 62 temsirolimus 62 nonclinical studies 62 HCV replicon 62 gemcitabine cisplatin 62 Cerashield 62 midstage clinical 62 Ocrelizumab 62 Targretin 62 VA# [002] 62 PSN# [002] 62 pharmacodynamic markers 62 JAK2 inhibitor 62 Solazed TM 62 LAB CGRP 62 Torisel 62 IGF 1R inhibitor 62 vinorelbine tartrate 62 Phase IIa clinical 62 Enzastaurin 62 CCR5 inhibitor 62 R sorafenib tablets 61 isatoribine 61 relapsed refractory multiple myeloma 61 ATL# [001] 61 humanized anti 61 ISTODAX 61 IRX 2 61 Aurora kinase inhibitor 61 BOLDER II 61 palifosfamide 61 RhuDex ® 61 Diabetic Macular Edema 61 bortezomib Velcade 61 OvaRex R 61 Pimavanserin 61 ZK EPO 61 BCX# 61 davunetide intranasal AL 61 MGCD# [001] 61 treatment naïve genotype 61 evaluating bafetinib 61 ONCONASE R 61 secondary efficacy endpoints 61 azilsartan medoxomil 61 Nasdaq IDRA today 61 IgG1 monoclonal antibody 61 NS5B polymerase 61 Canvaxin TM 61 low dose cytarabine 61 INTEGRILIN 61 Gammagard Liquid 61 BENICAR HCT 61 Vascugel 61 maximally tolerated dose 61 cyclophilin inhibitor 61 Azedra ™ 61 Vernakalant 61 OLYMPIA registry 61 dose escalation phase 61 TRO# 61 PROCHYMAL 61 ACAPODENE 61 protease inhibitor PI 61 ALN HPN 61 Talabostat 61 valopicitabine 61 NATRECOR ® 61 mTOR inhibition 61 Ceflatonin R 61 FOLFIRI chemotherapy 61 Motesanib 61 irbesartan 61 Phase 2b monotherapy 61 retaspimycin 61 Ridaforolimus 61 MIRCERA 61 rilonacept 61 TAXUS IV 61 PREOS R 61 chimeric monoclonal antibody 61 oral salmon calcitonin 61 isotype 61 NV1FGF 61 CCR5 receptor antagonist 61 NVA# 61 trials RCTs 61 marketed pegylated interferons 61 samalizumab 61 prospective multicenter 61 evaluating Xcytrin 61 miRview ™ squamous 61 oral renin inhibitor 61 histone deacetylase HDAC inhibitor 61 ADP receptor antagonist 61 Squalamine 61 NSCLC tumors 61 HepaSphere 61 small molecule Hedgehog 61 nucleoside analog 61 lasofoxifene 61 ancrod 61 HuMax CD# 61 Phase IIb trials 61 Pivotal Phase III 61 Neuradiab 61 ascending dose 61 anticancer compound 61 potent antitumor activity 61 IMPACT DCM 61 Zybrestat 61 dose cohort 61 #th Annual Interscience 61 custirsen 61 MAP# 61 varespladib 61 ORENCIA R 61 CCR5 mAb 61 HuMax HepC 61 vascular disrupting 61 apricitabine ATC 61 DCCR 61 radezolid 61 delafloxacin 61 Anturol TM 61 nanopharmaceutical 61 REMUNE R 61 bevacizumab Avastin R 61 UVIDEM 61 sunitinib Sutent 61 novel emulsion formulation 61 MCSP respectively 61 cariprazine 61 mg/m2 cohort 61 nitric oxide donating prostaglandin 61 oral Xeloda 61 adecatumumab MT# 61 Neulasta R 61 oral gallium 61 somatostatin analog 61 INCB# [003] 61 Ixempra 61 Epratuzumab 61 phase III isavuconazole 61 melphalan prednisone 61 Atrasentan 61 Lp PLA 2 61 Fodosine 61 LCP AtorFen 61 pegylated interferons 61 ABSORB clinical 61 Tezampanel 61 talabostat 61 pharmacokinetic characteristics 61 paclitaxel poliglumex 61 doxorubicin HCl liposome injection 61 TMC# [002] 61 PROVENGE sipuleucel T 61 motesanib diphosphate 61 oral JAK1 61 investigational immunotherapy 61 APEX AMI trial 61 Tekamlo 61 Vidaza ® 61 CINOD 61 doxorubicin cyclophosphamide 61 delipidation 61 deferiprone 61 GeoVax vaccine 61 Clinical Antipsychotic Trials 61 Cloretazine ® 61 monoclonal antibody mAb 61 AP# [003] 61 metastatic malignant 61 Phase IIb randomized 61 EndoTAGTM 1 61 TLK# 61 multicenter clinical 61 cMET 61 Alinia 61 BMS # 61 pharmacodynamic properties 61 Cleviprex TM clevidipine 61 Aurora kinase 61 Hedgehog antagonist 61 immatics 61 Randomized Double blind 61 TELCYTA 61 ENDEAVOR IV 61 RG# ITMN 61 Phase III placebo controlled 61 Clonicel 61 investigational monoclonal antibody 61 Thiarabine 61 MAXY alpha 61 mTOR inhibitor 61 Phase 1b 61 latrepirdine 61 evaluating Vectibix 61 SinuNase ™ 61 atrasentan 61 TLR antagonists 61 thalidomide Thalomid 61 peptide antigens 61 SAR# [002] 61 budesonide foam 61 Nexavar ® 61 Tracleer R 61 Toraymyxin TM 61 Fibrillex TM 61 prokinetic agent 61 dosage regimens 61 Phase III ADT 61 CYC# 61 ZD# [001] 61 ASCO abstract 61 ADAGIO study 61 icatibant 61 MET amplification 61 TLR9 agonist 61 Fc fusion protein 61 corticosteroid dexamethasone 61 PI3K inhibitor 61 NSABP 61 RE LY trial 61 anti amnesic 61 2 methoxyestradiol 61 glufosfamide 61 PROactive Study 61 HuMax TAC 61 adipiplon 61 Curaxin CBLC# 61 Elotuzumab 61 INxin TM 61 Phase 1a 61 HCD# [002] 61 Ceflatonin 61 CD3 monoclonal antibody 61 LEUKINE 61 octreotide implant 61 randomized multicenter trial 61 LibiGel ® 61 HepeX B TM 61 epothilones 61 Omacetaxine 61 AzaSite Plus 61 FAME Study 61 histone deacetylase inhibitor 61 sodium glucose cotransporter 61 JAK1 61 Initiates Phase II 61 IMiDs ® compound 61 PF # [002] 61 Marqibo TM 61 placebo controlled randomized 61 staphylococcal vaccine 61 Urocidin TM 61 controlled multicenter 61 Dextofisopam 61 ARRY # 61 oncolytic vaccine 61 HyQ 61 ALB # 61 Capesaris 61 Renal Cell Carcinoma RCC 61 Denufosol 61 Phase IIIb study 61 Phase Ib clinical trials 61 Akt activation 61 PEGylated interferon 61 immunotherapeutic agent 61 CHARISMA trial 61 VitiGam 61 pharmacodynamics PD 61 investigational compounds 61 angiotensin analog 61 antitumor effects 61 Panzem R 61 Vidaza R 61 TG MV 61 NATRECOR R 61 vascular disrupting agents 61 StemEx 61 SNT MC# 61 paclitaxel Taxol R 61 MEK inhibitor 61 rALLy trial 61 Romiplostim 61 AMPK activators 61 hypoxia activated prodrug 61 nab paclitaxel 61 ENESTnd 61 Yondelis ® 61 albinterferon alfa 2b 61 Panzem NCD 61 safety tolerability pharmacokinetic 61 AAG geldanamycin analog 61 Meta analyzes 61 Phase III randomized controlled 61 Actimmune ® 61 Phase III confirmatory 61 celgosivir 61 compound INCB# 61 Nasdaq ONXX today 61 viral kinetics 61 Randomized controlled 61 rxRNA 61 ISENTRESS 61 noninfectious uveitis 61 palifosfamide Zymafos TM 61 Vidofludimus 61 evaluating satraplatin plus 61 Vilazodone 61 PRE SURGE 61 Vectibix monotherapy 61 SYNTAX trial 61 Diamyd ® 61 TELINTRA 61 NADiA 61 Genasense ® oblimersen 61 antibody MAb 61 somatostatin analogue 61 dimeglumine 61 registrational studies 61 carboplatin paclitaxel 61 HuMax CD#b 61 PROSTVAC VF 61 midstage trials 61 antisense inhibitors 61 IPL# 61 plasma pharmacokinetics 61 KB# [002] 61 cleavable linker 61 Triapine R 61 BioNumerik 61 Canvaxin 61 microtubule inhibitor 61 GV# [001] 61 BLA filing 61 Oracea TM 61 AIM HIGH 61 bapineuzumab AAB 61 Octreolin 61 oxaliplatin Eloxatin 61 cardio renal 61 relapsed ovarian cancer 61 MAGE A3 61 DAVANAT 61 omacetaxine mepesuccinate 61 PROactive study 60 Achieves Primary Endpoint 60 Seliciclib 60 Blinatumomab 60 SinuNase TM 60 NOD SCID mice 60 gepirone ER 60 acetonide FA 60 Solorel 60 naltrexone SR 60 CLARITY study 60 dose proportionality 60 RoACTEMRA 60 RE SURGE 60 novel nucleoside analog 60 Pralatrexate 60 BRILINTA 60 RenalGuard System TM 60 active moiety 60 zanolimumab